B Cells in Idiopathic Nephrotic Syndrome

NACompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 2, 2019

Primary Completion Date

November 7, 2024

Study Completion Date

November 7, 2024

Conditions
Nephrotic Syndrome
Interventions
OTHER

Blood sampling

"Before the anti-CD20 monoclonal antibodies treatment (e.g. Rituximab/Ofatumumab) and after 6, 9 and 12, 24 months from the first infusion the following blood samples will be collected for the analysis of lymphocyte subpopulations:~* 50/100 mL of blood (20 mL for pediatric patients) for Peripheral Blood Mononuclear Cells (PBMCs) isolation.~* 8 mL of blood (both adult and pediatric) to obtain serum. Serum will be obtained by standard centrifugation and PBMC will be isolated by Ficoll-Paque® density gradient centrifugation, according to manufacturer's instruction."

Trial Locations (1)

24020

"Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò", Ranica

All Listed Sponsors
lead

Mario Negri Institute for Pharmacological Research

OTHER

NCT05712369 - B Cells in Idiopathic Nephrotic Syndrome | Biotech Hunter | Biotech Hunter